Abstract Lipidomics is a new frontier of omics research and offers much promise for new-generation biomarkers for common complex phenotypes such as hyperlipidemia (HL) and cardiovascular diseases (CVDs). HL is a disorder characterized by increased levels of blood lipids and is a well-established risk factor for CVD. Traditional clinical markers for prognosis of hyperlipidemic individuals are inadequate to forecast or diagnose cardiac events. In this expert review, lipidomic profiles from recent HL and CVD studies were compared with the normolipidemic profile prepared from the Standard Reference Material. Our analysis showed that palmitoyl-lysophosphatidylcholine [LPC(16:0)], the most abundant LPC species in normolipidemic plasma, decreases in HL causative conditions such as high-fat diet, obesity, and diabetes. This is accompanied by increase in free fatty acids (FFAs) and ceramides (Cers). HL was also found to be characterized by increase in small-chain, saturated fatty acid content of diacylglycerols, triacylglycerols, and phosphatidylcholines (PCs). These factors were also associated with increased CVD risk. The decrease in LPC(16:0) in HL and CVD is consistent
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً